Document is current
Any future updates will be listed below
-
Authors
Cardoso, Fatima https://orcid.org/0000-0002-6692-2249
Hirshfield, Kim M.
Kraynyak, Kimberly A.
Tryfonidis, Konstantinos
Bardia, Aditya https://orcid.org/0000-0003-4885-1157
-
Funding
Funding for this research was provided by:
Merck & Co., Inc. | Merck Sharp and Dohme
- License Information
-
More Information
Article History
Received: 1 May 2024
Accepted: 14 October 2024
First Online: 6 December 2024
Competing interests
: <i>Fatima Cardoso</i>. Payment or honoraria for advisory boards or educational events from Amgen, Astellas/Medivation, AstraZeneca, Bayer, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung, Bioepis, Seagen, Teva, and Touchime. <i>Kim M. Hirshfield, Kimberly A. Kraynyak, and Konstantinos Tryfonidis</i>. Employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. <i>Aditya Bardia</i>. Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck & Co., Inc., Rahway, NJ, USA, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/AstraZeneca, Phillips, Eli Lilly, and Foundation Medicine. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck & Co., Inc., Rahway, NJ, USA, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/AstraZeneca, and Eli Lilly.
